BioSpace News Archive

BioCryst Pharmaceuticals, Inc. announced financial results for the third quarter ended September 30, 2021, and provided a corporate update.

Intercept Pharmaceuticals, Inc., a biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat progressive non-viral liver diseases, announced its financial results for the quarter ended September 30, 2021.

Oncorus, Inc., a viral immunotherapies company focused on driving innovation to transform outcomes for cancer patients, reported third quarter 2021 financial results and highlighted recent achievements and developments.

EyePoint Pharmaceuticals, Inc., a pharmaceutical company committed to developing and commercializing therapeutics to improve the lives of patients with serious eye disorders, announced financial results for the third quarter ended September 30, 2021 and highlighted recent corporate developments.

CareDx, Inc. today announced key data and presentations at the American Society of Nephrology (ASN) Kidney Week 2021, which will be held virtually from November 4-7, 2021.

Praxis Precision Medicines, Inc., a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies for central nervous system disorders characterized by neuronal imbalance, provided a corporate update and reported financial results for the third quarter ended September 30, 2021.

Revive Therapeutics Ltd. is pleased to announce it has entered into a research collaboration agreement with PharmaTher Holdings Ltd., a clinical-stage psychedelics biotech company, to evaluate the delivery of psilocybin with PharmaTher’s proprietary microneedle patch technology for neuropsychiatric disorders.

Solid Biosciences Inc. today provided a business update as well as financial results for the third quarter ended September 30, 2021.

Autolus Therapeutics plc, a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies, announced its operational and financial results for the third quarter ended September 30, 2021.

Insightec announced today that the U.S. Food and Drug Administration (FDA) has approved the Exablate® Neuro for treating advanced Parkinson’s Disease patients suffering from mobility, rigidity, or dyskinesia symptoms.